Arthrosi Therapeutics key facts
as of Oct 2026- Developer of biotechnology drugs designed to reduce flare and tophi in gout patients.
- Arthrosi Therapeutics is valued at approximately $1.5B as of Oct 2026, set at a merger or acquisition, Dec 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $298.8M across 7 recorded rounds; the latest was Later Stage VC ($60.9M) in Jun 2025.
- Notable investors include Heda Ventures, Viva BioInnovator, JMCR Family Office, Highlight Capital Partners, LTS Capital Advisors — 16 tracked in total.
- Arthrosi Therapeutics has filed 8 Form Ds with the SEC since 2018, most recently Jun 2025 ($60.9M sold to 13 investors).
- Status: Privately Held (backing).
Valued at $1.5B at a merger or acquisition, Dec 2025. Nothing has traded since.
- ·The complete investor list: 16 names
- ·Watch Arthrosi Therapeutics: the Monday email on marks, rounds and moves
Arthrosi Therapeutics funding rounds
7 roundsWho backs Arthrosi Therapeutics
16+Arthrosi Therapeutics valuation
Arthrosi Therapeutics was valued at $1.5 billion at a merger or acquisition in Dec 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Arthrosi Therapeutics raised?
Arthrosi Therapeutics has raised $299 million in total; 7 of its rounds are on record, from 2018 on. The largest on record was an $8.5 million early-stage round in May 2020; the most recent was a $60.9 million later-stage round in Jun 2025.
Arthrosi Therapeutics has filed 8 Form Ds with the SEC since 2018, most recently in Jun 2025 ($60.9 million sold to 13 investors).
Arthrosi Therapeutics investors
16 investors are on record for Arthrosi Therapeutics, including Heda Ventures, Viva BioInnovator, JMCR Family Office and Highlight Capital Partners. The later-stage round in Jun 2025 drew 13 investors.
About Arthrosi Therapeutics
Developer of biotechnology drugs designed to reduce flare and tophi in gout patients. The company provides clinical-stage research and development services focused on therapy for gout and chronic kidney disease, enabling medical professionals to provide strong uric acid reduction and the resolution of joint damage caused by tophi.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2018
- Employees
- 36
- Website
- arthrosi.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.